A matched analysis of the use of high flow nasal cannula for pediatric severe acute asthma

作者：Colin Rogerson, Samer Abu‐Sultaneh, L. Nelson Sanchez‐Pinto, Benjamin Gaston, Sarah E. Wiehe, Titus Schleyer, Wanzhu Tu, Eneida A. Mendonça · 发表于：Pediatric Pulmonology · 年份：2024 · DOI：10.1002/ppul.27233 · 被引用次数：7 · 研究领域：Asthma and respiratory diseases、Respiratory Support and Mechanisms、Inhalation and Respiratory Drug Delivery

RATIONALE: The high-flow nasal cannula (HFNC) device is commonly used to treat pediatric severe acute asthma. However, there is little evidence regarding its effectiveness in real-world practice. OBJECTIVES: We sought to compare the physiologic effects and clinical outcomes for children treated for severe acute asthma with HFNC versus matched controls. METHODS: This was a single-center retrospective matched cohort study at a quaternary care children's hospital. Children ages 2-18 hospitalized for severe acute asthma from 2015 to 2022 were included. Encounters receiving treatment with HFNC within the first 24 h of hospitalization were included as cases. Controls were primarily treated with oxygen facemask. Logistic regression 1:1 propensity score matching was done using demographics, initial vital signs, and medications. The primary outcome was an improvement in clinical asthma symptoms in the first 24 h of hospitalization measured as percent change from initial. MEASUREMENTS AND MAIN RESULTS: Of 693 eligible cases, 443 were matched to eligible controls. Propensity scores were closely aligned between the cohorts, with the only significant difference in clinical characteristics being a higher percentage of patients of Black race in the control group (54.3% vs. 46.6%; p = 0.02). Compared to the matched controls, the HFNC cohort had smaller improvements in heart rate (-11.5% [-20.9; -0.9] vs. -14.7% [-22.6;-5.7]; p < 0.01), respiratory rate (-14.3% [-27.9;5.4] vs. -16.7% [-31.5;0...